Do you have patients with a history of cardiac events and difficult to treat cholesterolemia? 

Consider these resources from SCAI on PCSK9 inhibitors: 

Featuring Michael Davidson, MD from the University of Chicago Pritzker School of Medicine on “LDL Management: Guideline Recommendations,” covering the 2018 AHA/ACC Multicity Guideline on the Management of Blood Cholesterol.  

Other topics include: 

  • Case Presentation, Emmanouil S. Brilakis, MD, PhD, FSCAI 
  • The Impact of PCSK-9 Inhibition of Coronary Plaque: GLAGOV and Beyond, Subhash Banerjee, MD, FSCAI,  
  • PCSK-9 Inhibition: Clinical Trial Data, Payal Kohli, MD 
  • Lipid Lowering in the COVID Era, Thomas Knickelbine, MD, FSCAI

This activity is sponsored by SCAI and supported by Amgen. 

Other resources from SCAI

Sharing knowledge, experience, research and knowledge.


Grand Rounds Tool Kit: PCSK9 Inhibitors

Resources including slides with presenter notes and videos from SCAI's PCSK9-i course titled, "Improving Clinical Outcomes After PC...